Sai Parenterals Ltd to Postpone Filing of Q3 and 9-Month Financial Results until May 15, 2026
Sai Parenterals Ltd has announced a delay in the submission of its financial results for the quarter and nine-month period ended on December 31, 2025. The company stated that the required data compilation and internal audits necessitate an extension, setting a new submission timeline of May 15, 2026.The delay is attributed to several operational factors, primarily involving the results of a recently acquired subsidiary. Sai Parenterals Ltd confirmed that the subsidiary, Noumed Pharmaceuticals PTY Limited, is undergoing an audit by foreign auditors, with the results expected in the first week of May, 2026.
The company explained that upon receiving the necessary financial data from Noumed Pharmaceuticals PTY Limited, it will require additional time to compile the Standalone and Consolidated Financial Results. This time is also needed to obtain the Limited Review Audit Report from the company's Statutory Auditors.
Sai Parenterals Ltd confirmed that the company's filing schedule has been adjusted as follows:
| Financial Metric | Period Covered | Previous Expected Submission Date | Revised Submission Date |
|---|---|---|---|
| Quarterly/9-Month Results | Quarter and 9 months ended December 31, 2025 | April 23, 2026 | May 15, 2026 |
| Annual Audited Results | Financial Year ended 2025-26 | N/A | On or before May 30, 2026 |
The company noted that the delay is purely unintentional and that efforts were made to meet the initial filing deadline. Sai Parenterals Ltd stated that it remains committed to maintaining high standards of corporate governance and transparency, ensuring that all financial results are published in compliance with market regulations.
SAIPARENT Stock Price Movement
Today, Sai Parenterals Limited shares edged higher to settle at ₹485.8, gaining 1.50% for the session. The stock saw robust trading activity, with a recorded volume of 190,381 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.